A randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease: Effects on quality of life and pulmonary function and preference
- Conditions
- chronic obstructive pulmonary disease
- Registration Number
- JPRN-UMIN000041342
- Lead Sponsor
- Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital
- Brief Summary
o significant differences in CAT or mMRC were reported, and no significant difference in FEV1 was observed. Although FVC was higher after Ume/ Vil and Tio/ Olo administration, and MMF and V25 were higher after Gly/Ind administration, the differences reported were small. In the final comparative questionnaire survey, patients reported better actual feeling of being able to inhale following Gly/ Ind administration, although no significant differences in adverse events or other evaluations were reported.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 75
Not provided
Inability to inhale unassisted; inability to perform spirometry tests; pregnancy; severe comorbidities affecting quality of life, including malignancy, cardiac failure, renal failure, or severe liver dysfunction; and comorbidity of severe prostatic hypertrophy and closed-angle glaucoma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in preference, QoL, respiratory function, and adverse events among three medications
- Secondary Outcome Measures
Name Time Method The relationship between the medication selected as the first rank in the final comparative questionnaire and the background factors of the patients